RESUMEN
O-linked fucose modification is rare and has been shown to occur almost exclusively within epidermal growth factor (EGF)-like modules. We have found that the EGF-CFC family member human Cripto-1 (CR) is modified with fucose and through a combination of peptide mapping, mass spectrometry, and sequence analysis localized the site of attachment to Thr-88. The identification of a fucose modification on human CR within its EGF-like domain and the presence of a consensus fucosylation site within all EGF-CFC family members suggest that this is a biologically important modification in CR, which functionally distinguishes it from the EGF ligands that bind the type 1 erbB growth factor receptors. A single CR point mutation, Thr-88 --> Ala, results in a form of the protein that is not fucosylated and has substantially weaker activity in cell-based CR/Nodal signaling assays, indicating that fucosylation is functionally important for CR to facilitate Nodal signaling.
Asunto(s)
Factor de Crecimiento Epidérmico , Fucosa/metabolismo , Proteínas de Homeodominio , Glicoproteínas de Membrana , Proteínas de Neoplasias/metabolismo , Transducción de Señal , Factores de Transcripción , Proteínas de Xenopus , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Células CHO , Cricetinae , Cartilla de ADN , Proteínas Ligadas a GPI , Glicosilación , Humanos , Péptidos y Proteínas de Señalización Intercelular , Espectrometría de Masas , Proteínas de la Membrana , Datos de Secuencia Molecular , Mutagénesis , Proteínas de Neoplasias/química , Proteínas de Neoplasias/genética , Mapeo Peptídico , Mutación Puntual , Homología de Secuencia de Aminoácido , Solubilidad , XenopusRESUMEN
A murine monoclonal antibody, CP.B8, specific for the extracellular portion of the human common gamma (gammac) chain, and its Fab fragment are shown to block the binding of IL-2 to COS-7 cells transfected with the cDNA for the full-length IL-2 receptor beta (IL-2Rbeta) and gammac chains, components which together comprise the intermediate affinity IL-2 receptor (IL-2R) expressed on the surface of resting T cells, NK cells, and on certain intestinal epithelial cells. To investigate the mechanism of this inhibition, the extracellular portions of the IL-2Rbeta and gammac chains were expressed and purified, and their interactions with each other and with IL-2 were studied by gel filtration and by surface plasmon resonance (SPR). By gel filtration, a stable ternary complex was formed by association of the three proteins, while no stable binary complexes were detected between any two of the three proteins. By SPR analysis, IL-2 was shown to associate rapidly with IL-2Rbeta, forming a binary complex with an equilibrium dissociation constant (Kd) of 800 nM, which permitted subsequent association of the gammac chain. Dissociation of the IL-2/IL-2Rbeta/gammac chain complex was significantly slower than dissociation of the IL-2/IL-2Rbeta complex. Using these model systems, we tested the ability of mAb CP.B8 to inhibit the association of the gammac chain with IL-2 and IL-2Rbeta. By gel filtration, mAb CP.B8 formed a stable complex with the gammac chain, preventing its association with IL-2 and IL-2Rbeta. MAb CP.B8 was also capable of dissociating the gammac chain already complexed with IL-2 and IL-2Rbeta. SPR analysis confirmed these findings and showed, in addition, that the Fab fragment of CP.B8 was also capable of inhibiting the association of the gammac chain with the IL-2/IL-2Rbeta complex. We conclude that mAb CP.B8 blocks the second step in the formation of the intermediate affinity IL-2R on the surface of transfected COS-7 cells by binding at or close to a region on the gammac chain that is involved in contact with IL-2 and/or IL-2Rbeta.
Asunto(s)
Anticuerpos Bloqueadores/farmacología , Anticuerpos Monoclonales/farmacología , Receptores de Interleucina-2/antagonistas & inhibidores , Receptores de Interleucina-2/inmunología , Secuencia de Aminoácidos , Animales , Técnicas Biosensibles , Cromatografía en Gel , Histidina/genética , Humanos , Fragmentos Fab de Inmunoglobulinas/farmacología , Interleucina-2/antagonistas & inhibidores , Interleucina-2/inmunología , Interleucina-2/metabolismo , Sustancias Macromoleculares , Ratones , Datos de Secuencia Molecular , Receptores de Interleucina-2/genética , Receptores de Interleucina-2/metabolismo , Proteínas Recombinantes/antagonistas & inhibidores , Proteínas Recombinantes/química , Proteínas Recombinantes/aislamiento & purificación , Proteínas Recombinantes/metabolismo , Solubilidad , TransfecciónRESUMEN
During hedgehog biosynthesis, autocatalytic processing produces a lipid-modified amino-terminal fragment (residues 24-197 in the human Sonic hedgehog sequence) that is responsible for all known hedgehog signaling activity and that is highly conserved evolutionarily. Published in vitro biochemical studies using Drosophila hedgehog identified the membrane anchor as a cholesterol, and localized the site of attachment to the COOH terminus of the fragment. We have expressed full-length human Sonic hedgehog in insect and in mammalian cells and determined by mass spectrometry that, in addition to cholesterol, the human hedgehog protein is palmitoylated. Peptide mapping and sequencing data indicate that the palmitoyl group is attached to the NH2 terminus of the protein on the alpha-amino group of Cys-24. Cell-free palmitoylation studies demonstrate that radioactive palmitic acid is readily incorporated into wild type Sonic hedgehog, but not into variant forms lacking the Cys-24 attachment site. The lipid-tethered forms of hedgehog showed about a 30-fold increase in potency over unmodified soluble hedgehog in a cell- based (C3H10T1/2 alkaline phosphatase induction) assay, suggesting that the lipid tether plays an important role in hedgehog function. The observation that an extracellular protein such as Shh is palmitoylated is highly unusual and further adds to the complex nature of this protein.
Asunto(s)
Ácido Palmítico/química , Proteínas/genética , Transactivadores , Animales , Línea Celular , Colesterol/química , Proteínas Hedgehog , Humanos , Ratones , Ratones Endogámicos C3H , Mapeo Peptídico , Proteínas/química , Proteínas/metabolismo , Ratas , Transducción de SeñalRESUMEN
The lymphotoxin-alpha beta complex (LT alpha beta) is found on the surface of activated lymphocytes and binds to a specific receptor called the LT beta receptor (LT beta R). In the mouse, signaling through this pathway is important for lymph node development and splenic organization, yet the biochemical properties of murine LT alpha and LT beta are essentially unknown. Here we have used soluble receptor-Ig forms of LT beta R and TNF-R55 and mAbs specific for murine LT alpha, LT beta, and LT beta R to characterize the appearance of surface LT alpha beta complexes and LT beta R on several common murine cell lines. Cells that bound LT beta R also bound anti-LT alpha and anti-LT beta mAbs in a FACS analysis. The ability of these reagents to discriminate between surface TNF and LT was verified by analysis of surface TNF-positive, LPS-activated murine RAW 264.7 monocytic cells. Primary mouse leukocytes from spleen, thymus, lymph node, and peritoneum were activated in vitro, and CD4+ and CD8+ T cells as well as B cells expressed surface LT ligand but not the LT beta R. Conversely, elicited peritoneal monocytes/macrophages were surface LT negative yet LT beta R positive. This study shows that on mononuclear cells, surface LT complexes and receptor are expressed similarly in mice and man, and the tools described herein form the foundation for study of the functional roles of the LT system in the mouse.
Asunto(s)
Linfocitos/química , Linfocitos/metabolismo , Linfotoxina-alfa/química , Proteínas de la Membrana/química , Factor de Necrosis Tumoral alfa/química , Animales , Anticuerpos Monoclonales/química , Especificidad de Anticuerpos , Linfocitos B/química , Línea Celular , Citometría de Flujo , Humanos , Hibridomas , Inmunoglobulinas/genética , Inmunoglobulinas/metabolismo , Linfocitos/inmunología , Linfoma de Células T , Linfotoxina-alfa/inmunología , Linfotoxina beta , Macrófagos , Proteínas de la Membrana/inmunología , Ratones , Ratas , Receptores del Factor de Necrosis Tumoral/genética , Receptores del Factor de Necrosis Tumoral/metabolismo , Proteínas Recombinantes de Fusión/metabolismo , Solubilidad , Especificidad de la Especie , Linfocitos T/química , Células Tumorales Cultivadas , Factor de Necrosis Tumoral alfa/inmunología , Factor de Necrosis Tumoral alfa/metabolismoRESUMEN
Human lymphotoxin-alpha (LT alpha) is found in a secreted form and on the surface of lymphocytes as a complex with a second related protein called lymphotoxin-beta (LT beta). Both secreted human LT alpha and TNF have similar biological activities mediated via the TNF receptors, whereas the cell surface LT alpha beta complex binds to a separate receptor called the LT beta receptor (LT beta R). The murine LT alpha and LT beta (mLT alpha and mLT beta) proteins have never been characterized. When recombinant mLT alpha was produced by either of several methods, the protein had a very low specific activity relative to that of human LT alpha in the conventional WEHI 164 cytotoxicity bioassay. The weak activity observed was inhibited by a soluble murine TNF-R55 Ig fusion protein (mTNF-R55-Ig), but not by mLT beta R-Ig. Coexpression of both mLT alpha and a soluble version of mLT beta in insect cells led to an LT alpha beta form that was cytotoxic in the WEHI 164 assay via the LT beta R. To determine whether natural mLT alpha-like forms with cytotoxic activity comparable to that of secreted human LT alpha were secreted from primary spleen cells, splenic lymphocytes were activated in various ways, and their supernatants were analyzed for cytotoxic activity. Using specific Abs to distinguish between mTNF and mLT, a TNF component was readily detected; however, there was no evidence for a secreted mLT alpha cytotoxic activity using this assay. Combined, these observations suggest that secreted mLT alpha may not play a role in the mouse via interactions with TNF-R55, and the ramifications of this hypothesis are discussed.
Asunto(s)
Citotoxicidad Inmunológica , Linfotoxina-alfa/química , Proteínas de la Membrana/química , Proteínas Recombinantes/química , Proteínas Recombinantes/inmunología , Secuencia de Aminoácidos , Animales , Anticuerpos Monoclonales/química , Pruebas Inmunológicas de Citotoxicidad , Humanos , Activación de Linfocitos , Linfotoxina-alfa/metabolismo , Linfotoxina-alfa/toxicidad , Linfotoxina beta , Sustancias Macromoleculares , Proteínas de la Membrana/metabolismo , Proteínas de la Membrana/toxicidad , Ratones , Ratones Endogámicos BALB C , Datos de Secuencia Molecular , Receptores del Factor de Necrosis Tumoral/fisiología , Proteínas Recombinantes/metabolismo , Solubilidad , Linfocitos T Citotóxicos/metabolismo , Células Tumorales Cultivadas , Factor de Necrosis Tumoral alfa/química , Factor de Necrosis Tumoral alfa/metabolismoRESUMEN
Certain monoclonal antibodies (MAbs) directed against CD4 can efficiently block HIV-1 replication in vitro. To explore CD4-directed passive immunotherapy for prevention or treatment of AIDS virus infection, we previously examined the biological activity of a nondepleting CD4-specific murine MAb, mu5A8. This MAb, specific for domain 2 of CD4, blocks HIV-1 replication at a post-gp120-CD4 binding step. When administered to normal rhesus monkeys, all CD4+ target cells were coated with antibody, yet no cell clearance or measurable immunosuppression occurred. However, strong anti-mouse Ig responses rapidly developed in all monkeys. In the present study, we report a successfully humanized form of mu5A8 (hu5A8) that retains binding to both human and monkey CD4 and anti-AIDS virus activity. When administered intravenously to normal rhesus monkeys, hu5A8 bound to all target CD4+ cells without depletion and showed a significantly longer plasma half-life than mu5A8. Nevertheless, an anti-hu5A8 response directed predominantly against V region determinants did eventually appear within 2 to 4 weeks in most animals. However, when hu5A8 was administered to rhesus monkeys chronically infected with the simian immunodeficiency virus of macaques, anti-hu5A8 antibodies were not detected. Repeated administration of hu5A8 in these animals resulted in sustained plasma levels and CD4+ cell coating with humanized antibody for 6 weeks. These studies demonstrate the feasibility of chronic administration of CD4-specific MAb as a potential means of treating or preventing HIV-1 infection.
Asunto(s)
Anticuerpos Monoclonales , Antígenos CD4/inmunología , Linfocitos T CD4-Positivos/inmunología , VIH-1/fisiología , Inmunización Pasiva/métodos , Replicación Viral , Secuencia de Aminoácidos , Animales , Anticuerpos Antiidiotipos/sangre , Anticuerpos Monoclonales/sangre , Anticuerpos Monoclonales/genética , Anticuerpos Monoclonales/inmunología , Secuencia de Bases , Linfocitos T CD4-Positivos/virología , Humanos , Región Variable de Inmunoglobulina/genética , Región Variable de Inmunoglobulina/inmunología , Depleción Linfocítica , Macaca mulatta , Ratones , Datos de Secuencia Molecular , Proteínas Recombinantes de Fusión , Síndrome de Inmunodeficiencia Adquirida del Simio/inmunologíaRESUMEN
The lymphotoxin (LT) protein complex is a heteromer of alpha (LT-alpha, also called tumor necrosis factor (TNF)-beta) and beta (LT-beta) chains anchored to the membrane surface by the transmembrane domain of the LT-beta portion. Both proteins belong to the TNF family of ligands and receptors that regulate aspects of the immune and inflammatory systems. The LT complex is found on activated lymphocytes and binds to the lymphotoxin-beta receptor, which is generally present on nonlymphoid cells. The signaling function of this receptor-ligand pair is not precisely known but is believed to be involved in the development of the peripheral lymphoid organs. To analyze the properties of this complex, a soluble, biologically active form of the surface complex was desired. The LT-beta molecule was engineered into a secreted form and co-expressed with LT-alpha using baculovirus/insect cell technology. By exploiting receptor affinity columns, the LT-alpha3, LT-alpha2/beta1, and LT-alpha1/beta2 forms were purified. All three molecules were trimers, and their biochemical properties are described. The level of LT-alpha3-like components in the LT-alpha1/beta2 preparation was found to be 0.02% by following the activity of the preparation in a WEHI 164 cytotoxicity assay. LT-alpha3 with an asparagine 50 mutation (D50N) cannot bind the TNF receptors. Heteromeric LT complexes were prepared with this mutant LT- alpha form, allowing a precise delineation of the extent of biological activity mediated by the TNF receptors. A LT-alpha3 based cytotoxic activity was used to show that the LT-alpha1/beta2 form cannot readily scramble into a mixture of forms following various treatments and storage periods. This biochemical characterization of the LT heteromeric ligands and the demonstration of their stability provides a solid foundation for both biological studies and an analysis of the specificity of the LT-bet a and TNF receptors for the various LT forms.
Asunto(s)
Linfotoxina-alfa/química , Proteínas de la Membrana/química , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Bioensayo , Cromatografía Líquida de Alta Presión , Citotoxinas/química , Cartilla de ADN/química , Humanos , Linfotoxina beta , Sustancias Macromoleculares , Ratones , Datos de Secuencia Molecular , Peso Molecular , Nucleopoliedrovirus , Proteínas Recombinantes , Solubilidad , SpodopteraRESUMEN
Surface lymphotoxin (LT) is a heteromeric complex of LT-alpha and LT-beta chains that binds to the LT-beta receptor (LT-beta-R), a member of the tumor necrosis factor (TNF) family of receptors. The biological function of this receptor-ligand system is poorly characterized. Since signaling through other members of this receptor family can induce cell death, e.g., the TNF and Fas receptors, it is important to determine if similar signaling events can be communicated via the LT-beta-R. A soluble form of the surface complex was produced by coexpression of LT-alpha and a converted form of LT-beta wherein the normally type II LT-beta membrane protein was changed to a type I secreted form. Recombinant LT-alpha 1/beta 2 was cytotoxic to the human adenocarcinoma cell lines HT-29, WiDr, MDA-MB-468, and HT-3 when added with the synergizing agent interferon (IFN) gamma. When immobilized on a plastic surface, anti-LT-beta-R monoclonal antibodies (mAbs) induced the death of these cells, demonstrating direct signaling via the LT-beta-R. Anti-LT-beta-R mAbs were also identified that inhibited ligand-induced cell death, whereas others were found to potentiate the activity of the ligand when added in solution. The human WiDr adenocarcinoma line forms solid tumors in immunocompromised mice, and treatment with an anti-LT-beta-R antibody combined with human IFN-gamma arrested tumor growth. The delineation of a biological signaling event mediated by the LT-beta-R opens a window for further studies on its immunological role, and furthermore, activation of the LT-beta-R may have an application in tumor therapy.
Asunto(s)
Apoptosis , Interferón gamma/farmacología , Linfotoxina-alfa/fisiología , Receptores del Factor de Necrosis Tumoral/fisiología , Transducción de Señal , Adenocarcinoma/patología , Animales , Anticuerpos Monoclonales/farmacología , Apoptosis/efectos de los fármacos , Muerte Celular/efectos de los fármacos , Línea Celular , Relación Dosis-Respuesta a Droga , Femenino , Citometría de Flujo , Humanos , Cinética , Receptor beta de Linfotoxina , Linfotoxina-alfa/inmunología , Ratones/inmunología , Receptores del Factor de Necrosis Tumoral/efectos de los fármacos , Proteínas Recombinantes/farmacología , Células Tumorales CultivadasRESUMEN
LFA3TIP, a fusion protein comprised of the first extracellular domain of LFA-3 fused to the hinge, CH2, and CH3 domains of human IgG1 inhibits responses of human and non-human primate T cells in vitro. In seeking to optimize the expression efficiency to prepare large quantities of LFA3TIP for primate studies, the protein was produced in both the CHO (Chinese hamster ovary) and murine NS-0 myeloma cell lines. Although LFA3TIP derived from these cell lines performs identically in vitro in CD2 receptor binding and T cell assays, examination of a pharmacodynamic marker-the reduction in CD2+ lymphocyte numbers-following the administration of equal doses of NS-0 or CHO derived LFA3TIP to baboons, suggested that the effect of the NS-0 derived material was less sustained. Pharmacokinetic analysis of the materials in baboons and mice shows that LFA3TIP produced by NS-0 cells is rapidly cleared from circulation relative to the product derived from CHO cells. The disparate clearance profiles correlate with distinct glycosylation patterns, with LFA3TIP derived from NS-0 cells being less extensively sialylated than that from CHO cells due in part to alpha-galactosyl capping of selected lactosamine moieties in the N-linked glycans of NS-0 derived LFA3TIP. Moreover, enzymatic desialylation of CHO derived LFA3TIP results in a glycoprotein with an evanescent serum profile when administered to mice and baboons. These results correlate the extent of N-acetylneuraminic acid capping with the clearance rates of LFA3TIP derived from the two distinct cell lines, and underscore the importance of evaluating glycosylation dependent PK parameters when choosing production cell lines for recombinant immunotherapeutics.
Asunto(s)
Adyuvantes Inmunológicos/farmacología , Adyuvantes Inmunológicos/farmacocinética , Antígenos CD58/farmacología , Inmunoglobulina G/farmacología , Proteínas Recombinantes de Fusión/farmacología , Proteínas Recombinantes de Fusión/farmacocinética , Linfocitos T/efectos de los fármacos , Adyuvantes Inmunológicos/biosíntesis , Animales , Antígenos CD2/genética , Antígenos CD2/inmunología , Células CHO/metabolismo , Cricetinae , Glicosilación , Humanos , Activación de Linfocitos , Ratones , Ratones Transgénicos , Papio , Polisacáridos/análisis , Proteínas Recombinantes de Fusión/biosíntesis , Linfocitos T/inmunología , Células Tumorales Cultivadas/metabolismoRESUMEN
Lymphotoxin (LT) is a cytokine related to TNF, found in human systems in both secreted and membrane bound forms. The well characterized secreted form is a trimer of a single protein, LT-alpha, whereas the surface form is composed of a complex between two related molecules, LT-alpha and LT-beta. Because there is a distinct receptor for the complex, the membrane form is believed to signal via events different from those elicited by TNF and secreted LT-alpha. By using a battery of anti-LT-alpha and LT-beta mAbs, it is clear that two LT surface forms exist on the surface of PMA-activated II-23 cells, a human T cell hybridoma. Assuming that these surface forms are trimers, a minor form appears early after induction having an apparent stoichiometry of LT-alpha 2/beta 1 and is recognized by one group of anti-LT-alpha mAbs and the p55-TNF receptor. The second and predominant form has an apparent LT-alpha 1/beta 2 composition and is recognized by a second group of pantrophic anti-LT-alpha mAbs and the LT-beta receptor. Neither of the heteromeric forms nor a putative LT-beta homotrimeric form were found to be secreted. The properties of surface LT on the II-23 cell system were similar to those of the surface LT forms on Chinese hamster ovary cells transfected with both LT-alpha and LT-beta genes and a number of lymphoid tumor lines. These experiments point toward the LT-alpha 1/beta 2 complex as the predominant membrane form of LT on the lymphocyte surface, and this complex is the primary ligand for the LT-beta receptor.
Asunto(s)
Anticuerpos Monoclonales/inmunología , Linfotoxina-alfa/inmunología , Proteínas de la Membrana/inmunología , Receptores del Factor de Necrosis Tumoral/metabolismo , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Células CHO , Chlorocebus aethiops , Cricetinae , Técnica del Anticuerpo Fluorescente , Glicosilación , Humanos , Hibridomas/inmunología , Cinética , Activación de Linfocitos , Receptor beta de Linfotoxina , Linfotoxina-alfa/química , Linfotoxina-alfa/metabolismo , Linfotoxina beta , Sustancias Macromoleculares , Proteínas de la Membrana/metabolismo , Datos de Secuencia Molecular , Pruebas de Precipitina , Unión Proteica , Conformación Proteica , Procesamiento Proteico-Postraduccional , Proteínas Recombinantes de Fusión/inmunología , Transducción de Señal , Solubilidad , Acetato de Tetradecanoilforbol/farmacología , Transfección , Células Tumorales CultivadasRESUMEN
Many biological processes depend on cell surface recognition of receptor-ligand pairs. Some receptors, such as the selectins, recognize specific carbohydrate structures as part of their ligands. The ability to synthesize such ligands for use in the study of cell adhesion mechanisms or as inhibitors of a variety of pathological conditions would be extremely useful. However, the chemical or enzymic in vitro synthesis of carbohydrate-based ligands has thus far been difficult and costly. We have used E-selectin and its carbohydrate ligand as a model system to test if it is possible to express specific carbohydrate structures on a secreted, glycosylated and easily purified scaffold protein and to use this newly modified protein as a functional adhesion molecule. We co-expressed a fucosyltransferase (ELFT) and a secreted immunoglobulin-LFA3 fusion protein (LFA31G) in the same cell to modify the carbohydrate structures on the secreted LFA3IG scaffold protein (we refer to this novel protein as X-LFA3IG). Using glycosidase digestion, lectin binding, carbohydrate composition analysis and antibody-binding assays, we show that approximately 50% of the potential N-linked carbohydrate sites on X-LFA3IG are, indeed, modified and that the modification is the addition of fucose. Furthermore, we show that X-LFA3IG contains epitopes recognized by anti-Slex antibodies, and, using an E-selectin-specific adhesion assay, we demonstrate that X-LFA3IG is a functional ligand for E-selectin. This in vivo approach for generating specific carbohydrate structures could be generalized to produce and purify large quantities of other biologically important carbohydrate structures.